Asthma Severity in Women: The Influence of Training and Menopause (ATOM)
The ATOM Study: Asthma Severity in Women: The Influence of Training and Menopause
Introduction: Late-onset asthma in women is characterized by poor disease control and reduced quality of life despite intensive treatment with inhaled steroid and beta2-agonist. The condition is further worsened at menopause due to the loss of estrogen leading to increased asthma exacerbation frequency, increased airway inflammation and decreased lung function. Exercise training may increase disease control of asthma patients, but to what extent the same effect is seen in postmenopausal women with late-onset asthma is unknown. These asthma patients represent a phenotype that is characterized by low eosinophilic airway inflammation, severe symptoms, moderate obesity and poor response to conventional medicine. Thus, our hypothesis is that regular physical exercise is especially associated with an improvement in asthma control in this phenotype. The aim of this project is to test this hypothesis and to assess whether an improvement is associated with reduced local and systemic inflammation, change in heart function, lung function and/or body composition.
Study design: 40 postmenopausal women with late-onset asthma are recruited via the outpatient clinic at the Respiratory Department at Bispebjerg Hospital and through advertisement. The participants are randomized 1:1 into two groups. One group performs supervised exercise training (spinning) three times per week for 12 weeks while the other group is a control group. Before and after the intervention asthma control, local and systemic inflammation, heart function and body composition is measured.
Results: Analysis will be performed to detect changes within and between the groups before and after intervention. Primary outcome is change in ACQ (Asthma Control Questionnaire). Local and systemic inflammation is measured by changes in bronchial challenge to methacholine, sputum cell count and blood tests. Furthermore, secondary outcomes include change in heart function measured by stress-echocardiography and change in body composition measured by Dual-energy X-ray absorptiometry (DEXA).
Conclusion: There are to date no prospective studies that can support recommendations containing asthma rehabilitation with supervised regular physical activity for postmenopausal women. Thus, this study will provide novel understanding of the importance of physical activity in a chronic disease such as asthma.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Overall study design
The study is a single-blinded randomized controlled intervention study. Forty postmenopausal women with late-onset asthma (>16 years at debut) are recruited from the asthma outpatient-clinic at Bispebjerg Hospital or other hospital/practitioner in the region and/or by advertisement. The participants are block-randomized into two groups of 20, where one group is control and the other undergoes a period of regular exercise training. The investigators will be blinded and will not know whether the subjects have trained or not.
Detailed study design
Participants allocated to the exercise training group undergo a training intervention consisting of 45 minutes of intermittent high intensity aerobic spinning training three times per week for 12 weeks. Participants allocated to the control group will continue usual care without training. No changes to current treatment will be made by the investigators on any of the groups.
The training will consist of short periods of high intensity intervals where subjects reach above 80% of maximal oxygen consumption. Spinning sessions will be fully supervised by trained instructors with a bachelor of sports and science or bachelor of medicine and conducted in the Department of Nutrition, Exercise and Sports, University of Copenhagen. Subjects will wear heart rate monitors to ensure adherence to the training protocol. Within two weeks, before and after the intervention, participants from both groups undergo 3 days of testing.
To ensure equal compliance with asthma medication both groups will receive daily electronic reminders. Once a week, all participants will be asked about their compliance to their medication.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Copenhagen, Dinamarca, 2400
- Respiratory research unit, Bispebjerg University Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Late onset asthma (Debut ≥ 16 years of age)
- ACQ ≥ 1.25
- Daily treatment for asthma (GINA 2 and above)
- Age 45 - 75
- Postmenopausal defined as no menstruation for 6 months, Serum Follicle stimulating hormone >20 International Units per Liter and P-Estradiol nmol/L <0.09
- BMI 25 - 35
- Positive bronchial challenge to methacholine, mannitol or positive reversibility to beta2-agonist now or historically
- Untrained (no participation in vigorous exercise for more than 1 hour per week during the last 2 months)
- Capable of exercising on a bike
Exclusion Criteria:
- Unable to speak and understand Danish or English.
- Current or former smokers (>6 months cessation) with >20 years of daily smoking with 20 cigarettes per day.
- Other respiratory disease of clinical significance
- Cardiovascular: Unstable ischemic heart disease, myocardial infarction within the last 12 months, symptomatic heart failure (EF <40%), symptomatic heart arrhythmia (documented with ECG), uncontrolled hypertension (>155/100)
- Any disorder that is not stable and in the opinion of the investigator could affect the safety of the subject throughout the study
- Subjects, who by investigators determination, will not be able to adhere to study protocol
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Aerobic exercise intervention
Aerobic exercise by high intensity interval training, 3 times per week for 12 weeks
|
High Intensity Interval Training (HIIT)
|
|
Sem intervenção: Control group
No intervention for 12 weeks
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Asthma control - Asthma Control Questionnaire (ACQ)
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in Asthma Control Questionnaire (ACQ) 7-point scale (0=no impairment, 6= maximum impairment for symptoms and rescue use)
|
-21 to 0 days before intervention and 0 to 14 days post intervention
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Heart Rate Variability
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in: - Heart rate variability |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart rhytm
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in: - Heart rhythm |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart Rate
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in: - electrocardiography |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Strain
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Measured by stress-echocardiography - Strain |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Ejection fraction
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Measured by stress-echocardiography - Ejection fraction |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Tricuspid annular plane systolic excursion
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Measured by stress-echocardiography - Tricuspid annular plane systolic excursion |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Right ventricular function
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Measured by stress-echocardiography - Right ventricular function |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Pulmonary pressure
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Measured by stress-echocardiography - Pulmonary pressure |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Lung covered cor
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Measured by stress-echocardiography - Lung covered cor |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Blood pressure
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Blood pressure
|
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Cardiac output
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Cardiac output
|
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Stroke volume
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Stroke volume
|
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Total peripheral resistance
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Total peripheral resistance
|
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Systemic inflammation - Leukocytes + differential cell count count
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Leukocytes + differential cell count count |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Systemic inflammation - Interleukin 6
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Interleukin 6 |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Systemic inflammation - Interleukin 8
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Interleukin 8 |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Systemic inflammation
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Other interleukins |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Systemic inflammation - Tumor Necrosis Factor alpha
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Tumor Necrosis Factor alpha |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Systemic inflammation - Total immunoglobulin E, Specific immunoglobulin E
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in
|
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Systemic inflammation - high sensitivity c reactive protein
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - high sensitivity c reactive protein |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Local airway inflammation - Sputum cell count
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Sputum cell count |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Local airway inflammation - Fraction of exhaled nitric oxide
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Fraction of exhaled nitric oxide |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Local airway inflammation - Hyperreactivity to inhaled methacholine
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Hyperreactivity to inhaled methacholine |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Body Composition
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Total body fat |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Body Composition
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Lean body mass |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Body Composition
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Muscle mass |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Body Composition
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Weight |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Microbiome
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in the microbiota in sputum, oral cavity and nasal cavity before and after the training intervention
|
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Compliance - Foster score
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Change in - Foster score Answers describe last weeks medicine use. Answers range form 0/7 - 7/7 with low values being worse. |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Other asthma related questionnaires - Nijmegen questionnaire
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Nijmegen questionnaire Values range from 0-64 and values below 20 are considered normal. |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Other asthma related questionnaires - Mini Asthma Quality of Life Questionnaire (miniAQLQ)
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Mini Asthma Quality of Life Questionnaire (miniAQLQ) 7-point Likert scale (7 = not impaired at all - 1 = severely impaired). |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Other asthma related questionnaires - Hospital Anxiety and Depression Scale (HADS) 2 items with 7 questions regarding anxiety and depression. (0 = no sign of depression/anxiety, 21 = maximal signs of anxiety/depression)
Prazo: -21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Hospital Anxiety and Depression Scale (HADS) |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Vibeke Backer, Physician, Respiratory Research Unit, Bispebjerg Hospital
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ATOM (Radius Health, Inc.)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .